Latest Pharma Insights
How Celltrion Is Making A Splash In Tenders, Formularies And Pharmacies
Celltrion’s newer biosimilars are translating European tender wins and US reimbursement gains into market share, supporting a stronger sales mix and margin expansion heading into the second half.
Generics Bulletin - August 19, 2026
Celltrion’s newer biosimilars are translating European tender wins and US reimbursement gains into market share, supporting a stronger sales mix and margin expansion heading into the second half.
Generics Bulletin - August 19, 2026
Lundbeck Lays Foundation To Scale Up From 2027
The Danish drugmaker can boast a transformed pipeline and steady revenue rises that should ensure a sustainable healthy future, according to CEO Charl van Zyl.
Scrip - August 19, 2026
The Danish drugmaker can boast a transformed pipeline and steady revenue rises that should ensure a sustainable healthy future, according to CEO Charl van Zyl.
Scrip - August 19, 2026
Moderna And Merck’s mRNA Cancer Combo Shines In Phase III Melanoma Trial
Moderna shares nearly doubled premarket on the topline, with detailed results due at an upcoming medical meeting and overall survival still maturing.
Scrip - August 19, 2026
Moderna shares nearly doubled premarket on the topline, with detailed results due at an upcoming medical meeting and overall survival still maturing.
Scrip - August 19, 2026
Outlook To Expand Ophthalmic Bevacizumab Empire With Pre-Filled Presentation
Outlook Therapeutics is exploring a pre-filled syringe version of its ophthalmic bevacizumab Lytenava, while eyeing Latin America, Asia, and MENA for further deals.
Generics Bulletin - August 19, 2026
Outlook Therapeutics is exploring a pre-filled syringe version of its ophthalmic bevacizumab Lytenava, while eyeing Latin America, Asia, and MENA for further deals.
Generics Bulletin - August 19, 2026
Semaglutide Sole-Supplier Status Brings Both Rewards And Challenges For Apotex In Canada
Apotex has found itself left as the only supplier of generic semaglutide in Canada after Dr Reddy’s dropped out and Aspen was unable to launch. But while the Canadian firm is reaping commercial benefits, it is also having to step up supply to meet demand.
Generics Bulletin - August 19, 2026
Apotex has found itself left as the only supplier of generic semaglutide in Canada after Dr Reddy’s dropped out and Aspen was unable to launch. But while the Canadian firm is reaping commercial benefits, it is also having to step up supply to meet demand.
Generics Bulletin - August 19, 2026
Why Tenet’s $30m Round Is Really A Bet On India’s Diagnostics Roll-Up
Tenet Diagnostics’ $30m raise from Tata Capital Healthcare Fund and Blue Earth Capital is less a routine growth round and more an early bet on which platform will consolidate India's fragmented, $10bn-plus diagnostics market first.
Medtech Insight - August 19, 2026
Tenet Diagnostics’ $30m raise from Tata Capital Healthcare Fund and Blue Earth Capital is less a routine growth round and more an early bet on which platform will consolidate India's fragmented, $10bn-plus diagnostics market first.
Medtech Insight - August 19, 2026
Bio-Thera Expands Dupixent Biosimilar Reach With MENA Deal
Bio-Thera has handed Avalon Pharma exclusive MENA rights to its proposed Dupixent biosimilar BAT2406, extending its international commercialization network as competition builds around the $17.8bn biologic.
Generics Bulletin - August 19, 2026
Bio-Thera has handed Avalon Pharma exclusive MENA rights to its proposed Dupixent biosimilar BAT2406, extending its international commercialization network as competition builds around the $17.8bn biologic.
Generics Bulletin - August 19, 2026
Regeneron’s Uveitis Setback Adds To String Of Recent Pipeline Challenges
Regeneron’s latest pipeline setback puts fresh focus on its remaining ophthalmology bets and the broader slate of clinical catalysts that will shape its growth outlook.
Scrip - August 19, 2026
Regeneron’s latest pipeline setback puts fresh focus on its remaining ophthalmology bets and the broader slate of clinical catalysts that will shape its growth outlook.
Scrip - August 19, 2026
UK Hopes Quantum Breast Cancer Imaging Can Lower NHS Wait Times
A £1.65m NIHR grant funds Imperial College’s quantum technique for reading infrared tumor signals via visible light — with NHS deployment and NICE engagement in its sights.
Medtech Insight - August 19, 2026
A £1.65m NIHR grant funds Imperial College’s quantum technique for reading infrared tumor signals via visible light — with NHS deployment and NICE engagement in its sights.
Medtech Insight - August 19, 2026
Sandoz’s Generics-Biosimilars Split Reaches US Leadership
Sandoz has appointed separate US heads for generics and biosimilars, extending its global push to give the two businesses more distinct leadership as their commercial dynamics increasingly diverge.
Generics Bulletin - August 19, 2026
Sandoz has appointed separate US heads for generics and biosimilars, extending its global push to give the two businesses more distinct leadership as their commercial dynamics increasingly diverge.
Generics Bulletin - August 19, 2026
HUTCHMED Advances Global Early Trials For First-In-Class Conjugates
HUTCHMED’s Guangxiu Dai talks to Scrip about the firm’s first-in-class antibody-targeted therapy conjugates and strategies for cross-border partnerships.
Scrip - August 19, 2026
HUTCHMED’s Guangxiu Dai talks to Scrip about the firm’s first-in-class antibody-targeted therapy conjugates and strategies for cross-border partnerships.
Scrip - August 19, 2026
Lundbeck Lays Foundation To Scale Up From 2027
The Danish drugmaker can boast a transformed pipeline and steady revenue rises that should ensure a sustainable healthy future, according to CEO Charl van Zyl.
Scrip - August 19, 2026
The Danish drugmaker can boast a transformed pipeline and steady revenue rises that should ensure a sustainable healthy future, according to CEO Charl van Zyl.
Scrip - August 19, 2026
Moderna And Merck’s mRNA Cancer Combo Shines In Phase III Melanoma Trial
Moderna shares nearly doubled premarket on the topline, with detailed results due at an upcoming medical meeting and overall survival still maturing.
Scrip - August 19, 2026
Moderna shares nearly doubled premarket on the topline, with detailed results due at an upcoming medical meeting and overall survival still maturing.
Scrip - August 19, 2026
Regeneron’s Uveitis Setback Adds To String Of Recent Pipeline Challenges
Regeneron’s latest pipeline setback puts fresh focus on its remaining ophthalmology bets and the broader slate of clinical catalysts that will shape its growth outlook.
Scrip - August 19, 2026
Regeneron’s latest pipeline setback puts fresh focus on its remaining ophthalmology bets and the broader slate of clinical catalysts that will shape its growth outlook.
Scrip - August 19, 2026
HUTCHMED Advances Global Early Trials For First-In-Class Conjugates
HUTCHMED’s Guangxiu Dai talks to Scrip about the firm’s first-in-class antibody-targeted therapy conjugates and strategies for cross-border partnerships.
Scrip - August 19, 2026
HUTCHMED’s Guangxiu Dai talks to Scrip about the firm’s first-in-class antibody-targeted therapy conjugates and strategies for cross-border partnerships.
Scrip - August 19, 2026
Why Tenet’s $30m Round Is Really A Bet On India’s Diagnostics Roll-Up
Tenet Diagnostics’ $30m raise from Tata Capital Healthcare Fund and Blue Earth Capital is less a routine growth round and more an early bet on which platform will consolidate India's fragmented, $10bn-plus diagnostics market first.
Medtech Insight - August 19, 2026
Tenet Diagnostics’ $30m raise from Tata Capital Healthcare Fund and Blue Earth Capital is less a routine growth round and more an early bet on which platform will consolidate India's fragmented, $10bn-plus diagnostics market first.
Medtech Insight - August 19, 2026
UK Hopes Quantum Breast Cancer Imaging Can Lower NHS Wait Times
A £1.65m NIHR grant funds Imperial College’s quantum technique for reading infrared tumor signals via visible light — with NHS deployment and NICE engagement in its sights.
Medtech Insight - August 19, 2026
A £1.65m NIHR grant funds Imperial College’s quantum technique for reading infrared tumor signals via visible light — with NHS deployment and NICE engagement in its sights.
Medtech Insight - August 19, 2026
US FDA Drug Inspections At Pre-Pandemic Levels; Domestic OIA Citations Exceed Global Average
Foreign inspections still lag, but mutual recognition agreements are helping to fill the gap. If partner nations’ activities are counted, inspections are now above their pre-COVID levels for biopharma facilities.
HBW Insight - August 18, 2026
Foreign inspections still lag, but mutual recognition agreements are helping to fill the gap. If partner nations’ activities are counted, inspections are now above their pre-COVID levels for biopharma facilities.
HBW Insight - August 18, 2026
US FDA Report On Pharma Quality Documents Success In Curbing OTC Contaminations
FDA notes success in responding to contaminations of diethylene glycol and ethylene glycol in OTC drugs and benzene OTC aerosols in its latest drug quality assurance inspections report.
HBW Insight - August 18, 2026
FDA notes success in responding to contaminations of diethylene glycol and ethylene glycol in OTC drugs and benzene OTC aerosols in its latest drug quality assurance inspections report.
HBW Insight - August 18, 2026
US Cosmetics Industry Pushes Back on China’s Trade-Busting GMP Certificate Requirement
As US regulators develop a trade board to manage bilateral trade with China, the US cosmetics industry is looking for solutions to cosmetics regulatory differences between the countries.
HBW Insight - August 18, 2026
As US regulators develop a trade board to manage bilateral trade with China, the US cosmetics industry is looking for solutions to cosmetics regulatory differences between the countries.
HBW Insight - August 18, 2026
How Celltrion Is Making A Splash In Tenders, Formularies And Pharmacies
Celltrion’s newer biosimilars are translating European tender wins and US reimbursement gains into market share, supporting a stronger sales mix and margin expansion heading into the second half.
Generics Bulletin - August 19, 2026
Celltrion’s newer biosimilars are translating European tender wins and US reimbursement gains into market share, supporting a stronger sales mix and margin expansion heading into the second half.
Generics Bulletin - August 19, 2026
Outlook To Expand Ophthalmic Bevacizumab Empire With Pre-Filled Presentation
Outlook Therapeutics is exploring a pre-filled syringe version of its ophthalmic bevacizumab Lytenava, while eyeing Latin America, Asia, and MENA for further deals.
Generics Bulletin - August 19, 2026
Outlook Therapeutics is exploring a pre-filled syringe version of its ophthalmic bevacizumab Lytenava, while eyeing Latin America, Asia, and MENA for further deals.
Generics Bulletin - August 19, 2026
Semaglutide Sole-Supplier Status Brings Both Rewards And Challenges For Apotex In Canada
Apotex has found itself left as the only supplier of generic semaglutide in Canada after Dr Reddy’s dropped out and Aspen was unable to launch. But while the Canadian firm is reaping commercial benefits, it is also having to step up supply to meet demand.
Generics Bulletin - August 19, 2026
Apotex has found itself left as the only supplier of generic semaglutide in Canada after Dr Reddy’s dropped out and Aspen was unable to launch. But while the Canadian firm is reaping commercial benefits, it is also having to step up supply to meet demand.
Generics Bulletin - August 19, 2026
Bio-Thera Expands Dupixent Biosimilar Reach With MENA Deal
Bio-Thera has handed Avalon Pharma exclusive MENA rights to its proposed Dupixent biosimilar BAT2406, extending its international commercialization network as competition builds around the $17.8bn biologic.
Generics Bulletin - August 19, 2026
Bio-Thera has handed Avalon Pharma exclusive MENA rights to its proposed Dupixent biosimilar BAT2406, extending its international commercialization network as competition builds around the $17.8bn biologic.
Generics Bulletin - August 19, 2026
Sandoz’s Generics-Biosimilars Split Reaches US Leadership
Sandoz has appointed separate US heads for generics and biosimilars, extending its global push to give the two businesses more distinct leadership as their commercial dynamics increasingly diverge.
Generics Bulletin - August 19, 2026
Sandoz has appointed separate US heads for generics and biosimilars, extending its global push to give the two businesses more distinct leadership as their commercial dynamics increasingly diverge.
Generics Bulletin - August 19, 2026
AI-Driven Chinese Biotechs Make Splash With Financing Deals, Again
AI-powered Chinese ventures Phil Rivers and Beyang raise around $30m apiece in their latest funding rounds backed by venture capital and private equity firms.
In Vivo - August 18, 2026
AI-powered Chinese ventures Phil Rivers and Beyang raise around $30m apiece in their latest funding rounds backed by venture capital and private equity firms.
In Vivo - August 18, 2026
IPF Pipeline’s Next Big Readout: Bristol’s Admilparant Pivotal Trial
In a disease with slow therapeutic progress, Boehringer Ingelheim’s Jascayd launch progress raises interest in Bristol Myers Squibb’s admilparant and other late-stage idiopathic pulmonary fibrosis candidates.
In Vivo - August 18, 2026
In a disease with slow therapeutic progress, Boehringer Ingelheim’s Jascayd launch progress raises interest in Bristol Myers Squibb’s admilparant and other late-stage idiopathic pulmonary fibrosis candidates.
In Vivo - August 18, 2026
Strategic Intent: The Rise Of Mid-Cap Dealmakers
In this episode of Strategic Intent, Scrip’s Jessica Merrill unpacks how biopharma’s small-to-mid-cap players are stepping up as serious acquirers, using M&A to extend growth beyond their first commercial successes.
In Vivo - August 18, 2026
In this episode of Strategic Intent, Scrip’s Jessica Merrill unpacks how biopharma’s small-to-mid-cap players are stepping up as serious acquirers, using M&A to extend growth beyond their first commercial successes.
In Vivo - August 18, 2026